Initial, interim long-term data from the ongoing ralinepag phase
3 ADVANCE EXTENSION open label study to be presented at a poster
discussion session
An annual update of the preliminary baseline data from the TETON
phase 3 studies of inhaled treprostinil in idiopathic pulmonary
fibrosis will be presented at a poster session
United Therapeutics Corporation (Nasdaq: UTHR), a public
benefit corporation, today announced that recent research across
its commercial and development portfolio will be presented at the
American Thoracic Society (ATS) International Conference in
San Diego on May 17-22, 2024. At ATS, United Therapeutics will host
an educational industry theater on implementing treprostinil
induction strategies in pulmonary hypertension, and the company is
sponsoring the ATS 2024 Women’s Forum.
“We look forward to presenting the latest data on several of our
key products and development programs,” said Andrew Nelsen,
PharmD, Vice President, Global Medical Affairs at United
Therapeutics. “Notably, our academic and industry collaborators
will present initial interim efficacy data from the ADVANCE
EXTENSION open label extension evaluating extended-release
ralinepag for pulmonary arterial hypertension and baseline data
updates for the ongoing TETON studies in idiopathic pulmonary
fibrosis. We are also pleased to unveil the exciting preliminary
findings from our collaboration with Tempus, a leader in artificial
intelligence and precision medicine, laying the foundation for
earlier identification of patients with pulmonary
hypertension.”
Posters, mini-symposia, and discussion sessions
include:
Mini Symposium, Sunday, May 19, 10:03 to 10:15 a.m. PT: A14 –
Metabolomic Signatures of Pulmonary Hypertension Associated with
Interstitial Lung Disease: A Post-hoc Analysis of the INCREASE
Study. Presented by Aaron B. Waxman, M.D., Ph.D., Brigham and
Women’s Hospital.
Thematic poster session, Sunday, May 19, 11:30 a.m. to 1:15 p.m.
PT: A46/P829 – Pulmonary Hypertension Screening Strategies in
Patients with Interstitial Lung Disease: A Survey of PHINDER Study
Sites. Presented by Eric Shen, PharmD, United Therapeutics.
Thematic poster session, Monday, May 20, 11:30 a.m. to 1:15 p.m.
PT: B48/P1259 – TETON Phase 3 Clinical Trials of Inhaled
Treprostinil in the Treatment of Idiopathic Pulmonary Fibrosis:
Annual Update of Preliminary Baseline Data. Presented by Steven
D. Nathan, M.D., Inova Fairfax Hospital.
Thematic poster session, Monday, May 20, 11:30 a.m. to 1:15 p.m.
PT: B48/P1260 – Study Design and Rationale for the TETON-PPF
Clinical Trial of Inhaled Treprostinil for the Treatment of
Progressive Pulmonary Fibrosis. Presented by Steven D. Nathan,
M.D., Inova Fairfax Hospital.
Thematic poster session, Tuesday, May 21, 11:30 a.m. to 1:15
p.m. PT: C62/P284 – Real-World Transition and Persistence to
Oral Treprostinil Therapy from Parenteral Prostacyclins in Patients
with Pulmonary Arterial Hypertension. Presented by Ali Ataya,
M.D., University of Florida.
Poster discussion session, Wednesday, May 22, 11:00 a.m. to 1:00
p.m. PT: D105/410 – Clinical Improvements with Parenteral
Induction Therapy in Intermediate-High Risk Patients With PAH: A
Sub-Group Analysis of the EXPEDITE Study. Presented by Chad
Miller, M.D., Piedmont Healthcare.
Poster discussion session, Wednesday, May 22, 11:00 a.m. to 1:00
p.m. PT: D105/420 – Initial Long-term Data from a Phase 3
Open-label Extension Study (ROR-PH-303) Evaluating Ralinepag for
the Treatment of Pulmonary Arterial Hypertension (ADVANCE
EXTENSION). Presented by Joan A. Barberà, M.D., Ph.D., Hospital
Clinic de Barcelona.
Poster discussion session, Wednesday, May 22, 11:00 a.m. to 1:00
p.m. PT: D102/502 – Structured EHR Data Underestimates
Prevalence and Misses Large Proportions of Patients with Pulmonary
Hypertension. Presented by RuiJun Chen, M.D., Tempus.
Poster discussion session, Wednesday, May 22, 11:00 a.m. to 1:00
p.m. PT: D102/503 – A Novel Phenotyping Pipeline to Improve
Identification of Patients with Pulmonary Hypertension in
Electronic Health Records. Presented by David Vidmar, Ph.D.,
Tempus.
Poster discussion session, Wednesday, May 22, 11:00 a.m. to 1:00
p.m. PT: D102/504 – ECG-based Machine Learning Model Identifies
Patients at High Risk for Incident Pulmonary Hypertension.
Presented by Greg Lee, Tempus.
Sponsored events include:
The ATS 2024 Women’s Forum, Monday, May 20, 11:45 a.m. to
1:15 p.m. PT featuring Zea Borok, M.D., ATSF, formerly of the
University of Southern California; Stephanie Davis, M.D., ATSF,
University of North Carolina at Chapel Hill; Sonia Buist, M.D,
Oregon Health & Science University; and Obianuju Ozoh, M.D.,
University of Lagos.
Industry Theater, Sunday, May 19, 12:30 to 1:00 p.m. PT –
Implementing Treprostinil Induction Strategies in Pulmonary
Hypertension. Presented by Chad Miller, M.D., Piedmont
Healthcare.
United Therapeutics: Enabling Inspiration
At United Therapeutics, our vision and mission are one. We use
our enthusiasm, creativity, and persistence to innovate for the
unmet medical needs of our patients and to benefit our other
stakeholders. We are bold and unconventional. We have fun, we do
good. We are the first publicly-traded biotech or pharmaceutical
company to take the form of a public benefit corporation
(PBC). Our public benefit purpose is to provide a brighter
future for patients through (a) the development of novel
pharmaceutical therapies; and (b) technologies that expand the
availability of transplantable organs.
You can learn more about what it means to be a PBC here:
unither.com/pbc.
Forward-Looking Statements
Statements included in this press release that are not
historical in nature are “forward-looking statements” within the
meaning of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include, among others, our goals of
innovating for the unmet medical needs of our patients and to
benefit our other stakeholders, furthering our public benefit
purpose of developing novel pharmaceutical therapies and
technologies that expand the availability of transplantable organs.
These forward-looking statements are subject to certain risks and
uncertainties, such as those described in our periodic reports
filed with the Securities and Exchange Commission, that could cause
actual results to differ materially from anticipated results.
Consequently, such forward-looking statements are qualified by the
cautionary statements, cautionary language and risk factors set
forth in our periodic reports and documents filed with the
Securities and Exchange Commission, including our most recent
Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and
Current Reports on Form 8-K. We claim the protection of the safe
harbor contained in the Private Securities Litigation Reform Act of
1995 for forward-looking statements. We are providing this
information as of April 16, 2024, and assume no obligation to
update or revise the information contained in this press release
whether as a result of new information, future events, or any other
reason.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240416137116/en/
Dewey Steadman at (202) 919-4097
https://ir.unither.com/contact-ir/
United Therapeutics (NASDAQ:UTHR)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
United Therapeutics (NASDAQ:UTHR)
Gráfica de Acción Histórica
De May 2023 a May 2024